DURECT (NASDAQ:DRRX) Posts Earnings Results

DURECT (NASDAQ:DRRX) issued its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.05, Zacks reports. DURECT had a negative net margin of 279.77% and a negative return on equity of 328.25%. The firm had revenue of $2.17 million for the quarter, compared to the consensus estimate of $2.49 million. During the same quarter in the previous year, the company earned ($0.46) EPS.

DURECT Price Performance

Shares of NASDAQ:DRRX traded down $0.10 during trading on Thursday, reaching $1.23. 28,302 shares of the stock were exchanged, compared to its average volume of 163,879. DURECT has a 1-year low of $0.47 and a 1-year high of $3.36. The stock has a fifty day moving average of $1.47 and a two-hundred day moving average of $1.19. The firm has a market cap of $38.17 million, a price-to-earnings ratio of -1.40 and a beta of 1.03.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. HC Wainwright restated a “neutral” rating on shares of DURECT in a research report on Wednesday, May 22nd. StockNews.com lowered shares of DURECT from a “hold” rating to a “sell” rating in a research note on Thursday, August 8th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $21.00.

DURECT Company Profile

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.